4/19
02:01 pm
sls
Sellas Life Sciences Group: A Lottery Ticket With An Estimated 9x Payout [Seeking Alpha]
Low
Report
Sellas Life Sciences Group: A Lottery Ticket With An Estimated 9x Payout [Seeking Alpha]
3/28
04:19 pm
sls
SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
Medium
Report
SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
3/28
04:05 pm
sls
SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update
Medium
Report
SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update
3/28
07:00 am
sls
GenFleet and BeiGene Enter into Trial Collaboration for a Potentially First-in-class Combination Therapy to Initiate Phase Ib/II Study of GFH009 (CDK9 inhibitor) and BRUKINSA® (zanubrutinib) Treating Diffuse Large B Cell Lymphoma
High
Report
GenFleet and BeiGene Enter into Trial Collaboration for a Potentially First-in-class Combination Therapy to Initiate Phase Ib/II Study of GFH009 (CDK9 inhibitor) and BRUKINSA® (zanubrutinib) Treating Diffuse Large B Cell Lymphoma
3/26
07:47 am
sls
SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study [Yahoo! Finance]
Neutral
Report
SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study [Yahoo! Finance]
3/26
07:35 am
sls
SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study
Low
Report
SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study
3/19
04:10 pm
sls
SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules [Yahoo! Finance]
Low
Report
SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules [Yahoo! Finance]
3/19
04:05 pm
sls
SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
Low
Report
SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
3/19
08:56 am
sls
SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET [Yahoo! Finance]
Medium
Report
SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET [Yahoo! Finance]
3/19
08:47 am
sls
SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET
Low
Report
SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET
3/15
09:00 am
sls
SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
High
Report
SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
3/8
08:00 am
sls
SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships
Low
Report
SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships
3/1
08:30 am
sls
SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference
Medium
Report
SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference
2/29
08:00 am
sls
SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time
Low
Report
SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time
2/6
08:30 am
sls
SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotarget
High
Report
SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotarget
1/25
08:45 am
sls
SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference
Low
Report
SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference